Saturday November 21 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Arteriosclerosis Obliterans

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Arteriosclerosis Obliterans:

Pubmed Logo
Secondary aortoduodenal fistula caused on the suture line of the wrapping.
We investigated the impact of glycemic control on the emergence of...
2nd October, 2009
Pathol Int. 2009 Aug;59(8):598-600.
DOI Direct Link
Combined Distal Venous Arterialization and Free Flap for Patients with Extensive Tissue Loss.
BACKGROUND: We evaluated the mid-term outcome of distal venous...
22nd September, 2009
Department of Surgery, Asahikawa Medical University, Asahikawa, Japan. Ann Vasc Surg. 2009 Sep 16.
DOI Direct Link
Comparative study of the management of diabetic versus nondiabetic patients with atherosclerosis obliterans of the lower extremities.
The aim of this study was to identify the influence of diabetes mellitus...
18th September, 2009
Vascular Surgery Unit, Department of Surgery, Faculty of Medicine, Siriraj Vascular. 2008 Nov-Dec;16(6):333-9.
Is diabetic nephropathy a predicted risk factor?--Kaplan-Meier and multivariate analysis of confounding risk factors in off-pump coronary artery bypass grafting for chronic dialysis patients.
BACKGROUND: The purpose of this study was to investigate the preoperative...
3rd September, 2009
Department of Cardiovascular Surgery, National Cardiovascular Center, Circ J. 2009 Nov;73(11):2056-60. Epub 2009 Sep 2.
Long-term clinical outcomes for patients with lower limb ischemia implanted with G-CSF-mobilized autologous peripheral blood mononuclear cells.
BACKGROUND: Many studies have described the clinical effects of treating...
2nd September, 2009
Department of Surgery, Sapporo Hokuyu Hospital, Higashisapporo 6-6, Atherosclerosis. 2009 Aug 3.
DOI Direct Link

View more research publications.

Press Releases About Arteriosclerosis Obliterans:

BioPortfolio Logo
Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial 9th November, 2009 Harvest Technologies Corp.
PLYMOUTH, Mass., Nov. 9 /PRNewswire/ -- Harvest Technologies Corp. (www.harvesttech.com) announced today that the company sponsored 48-patient IDE clinical trial conducted at seven sites in the U.S.
Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia 9th July, 2009 Harvest Technologies Corp.
PLYMOUTH, Mass., July 9 /PRNewswire/ -- Harvest Technologies Corp. (www.harvesttech.com) announced today that the company sponsored 60-patient clinical trial conducted at Sri Ramachandra Medical
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans 2nd June, 2009 PARI Pharma
MONTEREY, Calif., June 2 /PRNewswire/ -- This month's Journal of Aerosol Medicine and Pulmonary Drug Delivery features positive Phase Ib clinical trial results for PARI Pharma's L-CsA,
Isis and Collaborators Present New Research at the ATVB Annual Conference 1st May, 2009 Isis Pharmaceuticals, Inc.
WASHINGTON and CARLSBAD, Calif., May 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Isis and collaborators presented data on numerous advanced programs from
VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque 1st May, 2009 VIA Pharmaceuticals, Inc.
Data Presented at American Heart Association ATVB Conference Shows Reduction in Non-Calcified Plaque Volume and Fewer New Plaque Lesions in Treated Patients WASHINGTON and SAN FRANCISCO, May 1

Arteriosclerosis Obliterans Clinical Trials:

Clinical Trials Logo
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related Biomarker

Arteriosclerosis Obliterans Patents:

USPTO Logo
US Patent No.Title
6969711 Cyclic diamine compounds and medicine containing the same
7179817 Carboxylic acid derivatives and drugs containing the same as the active ingredient
7183306 Pyrazole derivatives
7192976 Small molecule modulators of hepatocyte growth factor (scatter factor) activity
7205302 Heterocyclic compound derivatives and medicines

View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Arteriosclerosis Obliterans scientists - we have details of around 381 individuals working on Arteriosclerosis Obliterans .


This page has been viewed 567 times
Recent Search Terms used to find this page: atherosclerosis obliterans | in the may 26 arterosclerosis | arteriosclerosis obliterans | arteriosclerosis obliterans | arteriosclerosis obliterans | arteriosclerosis obliterans medical treatment pdf | arterioesclerosis.pdf | arteriosclerosis pdf | atheroschlerosis obliterans | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Arteriosclerosis Obliterans across BioPortfolio, or for Arteriosclerosis Obliterans Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.